Topical Niclosamide for Eczema: A Strong Bacterial Endpoint Was Not a Significant Symptom Advantage
Educational information from Dr. Arsy Editorial, checked November 9, 2026. Sources do not endorse #003. Individual treatment decisions belong with your clinician.
A treatment that lowers bacteria on eczema lesions may sound as though it must also improve the rash or itch. A short topical-niclosamide study shows why those outcomes need separate reading. It found a clear microbiological signal for one dosing schedule, without a significant active-versus-vehicle advantage in the measured clinical scores.
The 2022 paper describes an earlier, tightly selected trial
The primary full-text report studied ATx201 OINTMENT 2%, containing niclosamide, in a single-center trial conducted from December 2016 to March 2018. Adults aged 18–70 with localized eczema lesions and a specified minimum Staphylococcus aureus count were eligible. Forty-three patients were randomized, but seven were discontinued on day one because their bacterial counts were below the required threshold. The full analysis therefore included 36 patients.
There were 18 patients in each application-frequency group. Each person received active ointment on one selected lesion and matching vehicle on another, with a third lesion left untreated. Thus, the active and vehicle percentages within a schedule concern paired lesion treatments in the same people; they are not two separate groups of 18 different patients each.
| Finding | Numbers | Meaning |
|---|---|---|
| Primary bacterial success | A roughly 100-fold reduction in colony-forming units per cm² after seven days | Not complete skin clearance or a 100-fold improvement in eczema. |
| Twice-daily schedule | 17/18 active lesions (94.4%) versus 7/18 vehicle (38.9%); P≈0.0016 | Significant bacterial-endpoint difference. |
| Once-daily schedule | 9/18 active (50.0%) versus 6/18 vehicle (33.3%); P=0.18 | No significant primary bacterial-endpoint difference. |
| Clinical lesion scores | IGA, modified EASI and itch improved from baseline | No significant active-versus-vehicle difference in either dosing group. |
A microbiome result is not a symptom cure
The investigators also found an increase in Shannon diversity after twice-daily treatment. That index describes the distribution of organisms in a sample; it is not a patient-reported comfort score. The modified EASI evaluated a target lesion on a 0–12 scale, rather than the standard whole-body EASI result commonly quoted from systemic eczema trials.
The paper used language about bacterial eradication for its reduction threshold. Passing that threshold does not necessarily mean zero bacteria remain. Vehicle also reduced bacterial counts; the authors discussed possible activity of the polyethylene-glycol vehicle component. That makes comparison against the actual vehicle more informative than comparison against baseline alone.
Short-term tolerability does not settle long-term use
Treatment lasted seven days, with an end-of-study visit on day 14. Local reactions were reported, though described as mild or moderate and resolving without treatment interruption; systemic events were rated unrelated or unlikely related. The absence of a major safety signal in this small selected trial cannot establish universal tolerance, infant safety or long-term safety. Limited resistance findings in laboratory experiments and day-seven isolates likewise cannot guarantee that resistance will never develop.
The research received funding including UNION therapeutics and Innovation Fund Denmark. Several authors were company employees, shareholders, option holders, advisors or patent inventors. Those relationships are relevant context, even though the paper states that funders had no role in the study’s design, analysis or publication decisions.
What to ask before treating a bacterial test result
Do not make a skin preparation from oral or nonhuman niclosamide products. This study tested a particular formulation under a protocol; its findings do not establish an interchangeable home treatment. Ask a clinician whether there is infection requiring treatment, colonization without infection, or another explanation for symptoms. Read our skin-microbiome guide, early-versus-later microbiome trials, return-to-sport questions after infection and bleach-bath evidence explanation.
Dr. Arsy Moisturizer #003 supports cosmetic hydration, moisture-barrier support and ordinary dry-skin comfort. It is not niclosamide, an antibacterial treatment or an eczema medicine. None of this study’s bacterial or clinical findings transfers to #003.